Every material Form 8-K PUMA BIOTECHNOLOGY, INC. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Puma Biotechnology reported third-quarter 2026 results, with total revenue up slightly to $55.1 million from $54.5 million while GAAP net income fell to $6.0 million from $8.8 million. The company raised its full-year 2026 net income outlook to $20–22 million from $17–20 million, but its total revenue outlook was narrowed, with the top end lowered to $227 million from $231 million.
Q3 2026 net product revenue was $54.1 million, up from $51.9 million in Q3 2025; royalty revenue was $1.0 million, down from $2.6 million.
Q3 2026 GAAP net income was $6.0 million, or $0.11 per diluted share, compared with $8.8 million, or $0.17 per diluted share, in Q3 2025.
Full-year 2026 net income outlook was raised to $20–22 million from $17–20 million; total revenue outlook is $224–227 million versus $224–231 million previously.
Cash, cash equivalents and marketable securities were $108.5 million at September 30, 2026.
Puma Biotechnology reported second-quarter 2026 total revenue of $56.5 million, up from $52.4 million a year earlier, and net income of $8.2 million, or $0.16 per diluted share, versus $5.9 million, or $0.12, in the second quarter of 2025. The company raised its full-year 2026 total revenue and net income outlook, citing increased demand for NERLYNX, but first-half net income fell to $4.4 million from $8.8 million.
Q2 2026 total revenue was $56.5 million versus $52.4 million; net product revenue was $53.6 million versus $49.2 million.
Q2 2026 net income was $8.2 million, or $0.16 per diluted share, versus $5.9 million, or $0.12, in Q2 2025.
Full-year 2026 net income outlook raised to $17–$20 million from $16–$19 million; total revenue outlook raised to $224–$231 million from $222–$229 million.
First-half 2026 net income was $4.4 million, or $0.08 per diluted share, versus $8.8 million, or $0.18, in the first half of 2025.
Puma Biotechnology reported first quarter 2026 results, with total revenue of $44.8 million, down from $46.0 million a year earlier, and a GAAP net loss of $3.8 million, compared with net income of $3.0 million in the first quarter of 2025. The company raised its full-year 2026 total revenue and net income outlook, and said it repaid its remaining debt on May 4, 2026.
Total revenue was $44.8 million versus $46.0 million in Q1 2025; net product revenue was $42.0 million versus $43.1 million.
GAAP net loss of $3.8 million, or $0.07 per share, versus net income of $3.0 million, or $0.06 per share, a year earlier.
Full-year 2026 total revenue outlook raised to $222–$229 million from $214–$221 million; net income outlook raised to $16–$19 million from $10–$13 million.
Final payment under the 2021 Note Purchase Agreement was remitted on May 4, 2026, reducing outstanding debt to zero.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PUMA BIOTECHNOLOGY, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →